| Literature DB >> 24281096 |
Piotr Rutkowski1, Marcin Zdzienicki, Zbigniew I Nowecki, Alexander C J Van Akkooi.
Abstract
Surgery remains the mainstay of melanoma therapy, regardless of the tumor site. Only the early diagnosis combined with proper surgical therapy currently gives patients affected by this malignancy the chance for a full cure. The main goal of surgical therapy is to provide the local control of the disease and to secure long-term survival of the patient without reasonable functional and esthetic impairment. The recommended method of biopsy-excisional biopsy, as an initial diagnostic and, to some extent, therapeutic procedure-is performed under local anesthesia as an elliptical incision with visual clear margins of 1-3 mm and with some mm of subcutaneous tissue. The extent of radical excision of the primary tumor (or scar after excisional biopsy) is based on the histopathologic characteristics of the primary tumor and usually consists of 1-2 cm margins with primary closure. The philosophy behind conducted randomized clinical trials has been to find the most conservative surgical approach that is able to guarantee the same results as more demolitive treatment. This has been the background of the trials designed to define the correct margins of excision around a primary cutaneous melanoma. Much less definition can be dedicated to the surgical management of patients with non-cutaneous melanomas.Entities:
Year: 2010 PMID: 24281096 PMCID: PMC3835107 DOI: 10.3390/cancers2020824
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Practical considerations of excisional biopsy of a skin lesion suspicious of being melanoma (courtesy of W. Ruka) [15].
Clinical trials evaluating the width of radical excision surgical margins for primary melanoma.
| Breslow thickness [mm] | Clinical study | Patients(No.) | Margins [cm] | Overall survival (at years) | Ref. |
|---|---|---|---|---|---|
| French Cooperative Group | 336 | 2 | No difference(10-year) | [ | |
| ≤2 | Swedish Melanoma Group | 989 | 2 | No difference(5-year) | [ |
| WHO Melanoma Group Trial No. 10 | 612 | 1 | No difference(10-year) | [ | |
| 1–4 | Intergroup Melanoma Surgical Trial | 486 | 2 | No difference(6-year) | [ |
| ≥2 | UK Melanoma Study Group | 900 | 1 | Not reported; hazard ratio for death was similar in both groups (5-year) | [ |
| Swedish Melanoma Trial Group | 1,000 | 2 | Final results not reported; preliminary results indicated no difference (5-year) | [ |